Ambuterol Oral Solution

Chronic obstructive pulmonary disease (COPD), Asthma.

Adult: PO 10-20 mg once daily at bedtime.

Children 2-5 years: The recommended normal dose 10 mg (10 ml syrup). Children 6-12 years: The recommended normal dose 10 mg (10 ml syrup). The dose may be increased to 20 mg.

Renal impairment: CrCl (ml/min) <50 Initial dose should be halved.

Hepatic impairment: Severe: Not recommended.

Severe hepatic impairment; cirrhosis.

DM, hyperthyroidism, myocardial insufficiency, arrhythmias, susceptibility to QT-interval prolongation. Pregnancy.

Not Classi Although no teratogenic effects have been observed in animals after administration of bambuterol, caution is recommended during the first trimester of pregnancy. It is not known whether bambuterol or intermediary metabolites pass over to breast milk, so caution is recommended if bambuterol is administered to patients who are breast feeding. Terbutalin passes over to breast milk but an influence on the child is unlikely with therapeutic doses. Transient hypoglycemia has been reported in newborn pre-term infants after maternal ß2 agonist treatment.

Risk of hypokalaemia increased by co-admin of corticosteroids, diuretics or xanthines. Prolong the action of drugs e.g. suxamethonium.

Fine tremor of skeletal muscle (e.g. hands), palpitations and muscle cramps; tachycardia, tenseness and peripheral vasodilation.

Bambuterol HCl is a prodrug of terbutaline. It relaxes bronchial smooth muscle by selectively acting on ?2-receptors.

Ambuterol 5 mg/5 ml Oral Solution manufactured by APC Pharma Ltd.. Its generic name is Bambuterol Hydrochloride.